ClinicalTrials.gg
CompletedNCT06422507PHOTONiCUpdated Mar 31, 2026

A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

A Phase 3 interventional study of 8 mg aflibercept (BAY 86-5321) (High Dose) and 2 mg aflibercept (EYLEA, BAY 86-5321) in Diabetic Macular Edema, sponsored by Bayer. Completed at 52 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
333
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
8th of 53
333 · median 49
Started
2024
with 4 others
Phase 3
11 of 53
none open now
Registered
49th of 53
by date
Lead sponsor
9 of 53
Bayer

Among the 53 studies testing aflibercept in Macular Edema, this one is the 8th largest by enrollment, is one of 5 that started in 2024, is one of 11 in phase 3, and was the 49th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people who have diabetic macular edema.

Diabetic macular edema (DME) is a diabetes-related eye disorder. In DME, the macula, which is the central part of the retina at the back of the eye, swells up resulting in vision problems. This happens due to leakage of fluid from damaged blood vessels.

The study treatment, 8 milligram (mg) aflibercept is injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth and leakage of blood vessels at the back of the eye.

A lower dose of aflibercept (2 mg) is already approved for the treatment of DME. Based on the findings of another study, the higher dose of aflibercept (8 mg) is expected to reduce the frequency of injections required for treating DME while being equally safe and working as well as the lower dose. The higher dose could make it easier to treat DME and improve quality of life for people with DME.

The main purpose of this study is to learn if high-dose (8 mg) aflibercept given every 16 weeks works as well as low-dose (2 mg) aflibercept given every 8 weeks in Chinese participants.

For this, the researchers will compare the change in participants' 'best corrected visual acuity' (BCVA) after 48 weeks of starting the treatment. BCVA is the clearest vision a participant can have with the help of corrective lenses, such as glasses. It will be measured by the number of letters the participant can read on an eye chart. This is known as their Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.

Participants will be randomly (by chance) assigned to one of two treatment groups to receive study treatment as an injection into the eye up to Week 56:

  • 2 mg aflibercept every 8 weeks after receiving 5 initial monthly doses
  • 8 mg aflibercept every 16 weeks after receiving 3 initial monthly doses

Each participant will be in the study for around 63 weeks with up to 18 visits to the study site. This includes:

  • one visit up to 21 days before the treatment starts during which the doctors will confirm that the participant can take part in the study
  • 16 visits during which the treatment will be given. Most of these visits will have a gap of 4 weeks except for one visit that will happen a few days after the previous visit
  • one visit 4 weeks after the treatment ends

During the study, the doctors and their study team will:

  • check the participants' vision and their overall eye health using different eye tests
  • check participants' health by performing tests such as blood and urine tests
  • ask the participants questions about the disease and study treatment and how these impact their quality of life
  • ask the participants what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think they are related to the study treatment.

Access to study treatment after the end of this study is not planned. Participants can switch to available approved treatments for DME.

Read the detailed description

EYLEA (aflibercept 40 mg/mL solution for injection) at a dosage level of 2 mg administered intravitreally (IVT) is approved in over 100 countries for the treatment of DME. Despite the proven efficacy and safety of EYLEA in patients with DME, there remains an unmet need for alternative therapies that can decrease the burden of DME treatment via a reduction in the required frequency of IVT injections, while improving visual and anatomic outcomes. The overall one and two year results of PHOTON, a global phase 2/3 trial evaluating high dose (HD or 8 mg) aflibercept in participants with center-involved diabetic macular edema (DME), demonstrate the benefit of HD aflibercept for reducing the frequency of injections required for the treatment of DME while providing visual and anatomic outcomes non-inferior to and a safety profile indistinguishable from EYLEA, 2 mg aflibercept, the established standard of care for the treatment of DME. The observed reduction in the number of HD aflibercept injections required for the treatment of DME over 2 years in PHOTON is expected to translate into the benefit of reducing the burden of treatment and, thereby improving the quality of life for DME patients, their caregivers and health care providers. This study aims to investigate the efficacy and safety of HD aflibercept in Chinese participants with DME over 60 weeks with the primary objective of achieving non-inferior best corrected visual acuity (BCVA) with an extended dosing interval (every 16 weeks after 3 initial monthly injections) vs. 2 mg aflibercept (every 8 weeks after 5 initial monthly injections) similar to the results obtained in PHOTON. This study is designed to support the registration of HD aflibercept for the treatment of DME in China.

Primary Objective: The primary objective of the study is to determine if treatment with HD aflibercept at intervals of 16 weeks provides non-inferior best-corrected visual acuity (BCVA) compared to 2 mg aflibercept dosed every 8 weeks in Chinese participants

Secondary Objectives:

  • To determine the effect of HD aflibercept vs. 2 mg aflibercept on anatomic and other visual measures of response;
  • To evaluate the safety, immunogenicity and pharmacokinetics (PK) of HD aflibercept in Chinese participants.

Primary endpoint:

  • Change from baseline in BCVA by ETDRS letter score at Week 48

Secondary endpoints:

  • Change from baseline in BCVA by ETDRS letter score at Week 60
  • Participants gaining ≥15 letters at Week 48 and Week 60
  • Participants achieving an ETDRS letter score of at least 69 (approximate 20/40 Snellen equivalent) at Week 48
  • Participants with no IRF and/or no SRF in the center subfield at Week 48
  • Change from baseline in central subfield thickness (CST) at Week 48
  • Change from baseline in leakage on fluorescein angiography (FA) at Week 48
  • Change from baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ) total score at Week 48
  • Occurrence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Weeks 48 and 60
  • Participants developing a treatment-emergent ADA response or Nabs to aflibercept through EOS at Week 60
  • Systemic exposure to aflibercept as assessed by plasma concentrations of free, adjusted bound, and total aflibercept from baseline through Week 48 This study is a phase 3, multi-center, randomized, double-masked, active-controlled study in Chinese participants with DME involving the center of the macula to investigate the efficacy and safety of HD aflibercept versus 2 mg aflibercept.

The primary objective of the study is to determine if treatment with HD aflibercept at 16 week intervals provides non-inferior BCVA compared to 2 mg aflibercept dosed every 8 weeks in Chinese participants.

322 eligible participants randomized in a 1:1 ratio to the following 2 treatment groups:

  1. 2q8: 2 mg aflibercept every 8 weeks following 5 initial monthly doses (n=161) and
  2. HDq16: HD aflibercept every 16 weeks following 3 initial monthly doses (n=161). The study consists of a screening period, a treatment period, and an end of study (EOS) visit at Week 60. The study duration for a participant is approximately 63 weeks. The EOS is defined as the last visit of the last participant. No study treatment will be administered at the EOS visit at Week 60.

HD aflibercept is the sponsor's study intervention under investigation. The following intervention groups are included in the study:

  • 2 mg aflibercept every 8 weeks (2q8)
  • 8 mg aflibercept every 16 weeks (HDq16)
03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • DME
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Men or women ≥18 years of age
  • Chinese participants with type 1 or type 2 diabetes mellitus and diabetic macular edema (DME) with central involvement defined as CST ≥300 µm (or ≥320 µm on Heidelberg Spectralis) in the study eye as determined by the reading center at the screening visit and confirmed by the site at baseline visit
  • BCVA early treatment diabetic retinopathy study (ETDRS) letter score of 78 to 24 (approximate Snellen equivalent of 20/32 to 20/320) in the study eye at the screening and baseline visits with decreased vision determined to be primarily the result of DME
  • Women of (WOCBP) or men who are sexually active with partners of childbearing potential must agree to use highly effective prior to the initial dose/start of the first treatment, during the study, and for at least 4 months after the last administration of study intervention.

Key Exclusion Criteria:

  • Evidence of macular edema due to any cause other than diabetes mellitus in either eye
  • Active proliferative diabetic retinopathy in the study eye
  • Panretinal laser photocoagulation (PRP) or macular laser photocoagulation in the study eye within 12 weeks (84 days) of the screening visit
  • IVT anti-VEGF treatment (aflibercept, ranibizumab, bevacizumab, conbercept, faricimab, brolucizumab, pegaptanib sodium) in the study eye within 12 weeks (84 days) of the screening visit
  • Previous use of topical within 4 weeks (28 days) of the screening visit or of intraocular or periocular corticosteroids in the study eye within 16 weeks (112 days) of the screening visit, or ILUVIEN or OZURDEX IVT implants at any time
  • Prior ocular agents (that have not been approved) in either eye (e.g., IVT, suprachoroidal injections, ocular implants, etc.) at any time.
  • Previous treatment with an investigational or approved intraocular gene therapy or cell therapy in either eye at any time.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
333 participants (actual)

Study arms

  • Active comparator
    2 mg aflibercept

    Participants that will be enrolled to this treatment arm will receive 2 mg aflibercept every 8 weeks following 5 initial monthly doses starting at Baseline (visit 2) (2q8) for the chosen "study eye". Randomization will be stratified according to baseline Central subfield thickness (CST) (\<400 µm, ≥400 µm), baseline Best corrected visual acuity (BCVA) (\<60 vs. ≥60 ETDRS letters) and prior treatment for DME.

    Drug: 2 mg aflibercept (EYLEA, BAY 86-5321) · Other: Sham

  • Experimental
    8 mg aflibercept (high dose)

    Participants that will be enrolled to this treatment arm will receive 8 mg (high dose - HD) aflibercept every 16 weeks following 3 initial monthly doses, starting at Baseline (Visit 2) (HDq16) for the chosen "study eye". Randomization will be stratified according to baseline Central subfield thickness (CST) (\<400 µm, ≥400 µm), baseline Best corrected visual acuity (BCVA) (\<60 vs. ≥60 ETDRS letters) and prior treatment for DME.

    Drug: 8 mg aflibercept (BAY 86-5321) (High Dose) · Other: Sham

Interventions

  • High-dose (HD) aflibercept is the sponsor's study intervention under investigation. Dose formulation: solution in vial. Unit dose strength: 114.3 mg/mL, Dosage Level: 8 mg (70 µL), Route of Administration: Intravitreal (IVT) injection every 16 weeks following 3 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 3 mL glass vials. Each vial will be labeled as required per country requirement.

  • Aflibercept 2 mg is the sponsor's active comparator. Dose formulation: solution in vial. Unit dose strength: 40 mg/mL, Dosage Level: 2 mg (50 µL), Route of Administration: Intravitreal (IVT) injection every 8 weeks following 5 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 2 mL glass vials. Each vial will be labeled as required per country requirement. Aflibercept 2 mg for the non-study "fellow eye" treatment is considered an auxiliary medicinal product (AxMP) in this study. Fellow eye treatment will be allowed with 2 mg aflibercept, at the investigator's discretion for indications approved by governing authorities. The treated fellow eye will not be considered an additional study eye.

  • OtherSham

    To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56. Sham kits will be assigned for visits requiring sham injections. The sham kits are empty but should be handled in the same way as the active study intervention kits. Sham injections will be given on visits when an active injection is not planned. During the study treatment period all participants will receive either an active injection (8 mg or 2 mg aflibercept) or a sham injection (for masking purposes) following their assigned treatment group and eligibility for Dose regimen modification (DRM).

06

What researchers measure

Primary outcomes

  1. Change from baseline in Best corrected visual acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score at Week 48

    The primary endpoint is the change from baseline in BCVA at Week 48. Efficacy analyses will be conducted using the Full analysis set (FAS). The primary efficacy analysis will be a comparison between 2 comparative arms: HDq16 vs. 2q8. The primary efficacy variable (Change from baseline in BCVA by ETDRS letter score at Week 48) will be analyzed using FAS with an Mixed Model for Repeated Measurements (MMRM) analysis model. The model includes baseline BCVA as a covariate, treatment group, baseline CST category, baseline BCVA category, prior DME treatment, and visit as fixed effects, and interaction terms for treatment by visit and baseline BCVA by visit. A Kenward-Roger approximation will be used for the denominator degrees of freedom.

    Time frame: Week 0 (Baseline) to Week 48

Secondary outcomes

  1. Change from baseline in BCVA by ETDRS letter score at Week 60

    Time frame: Week 0 (Baseline) to Week 60

  2. Participants gaining ≥15 letters at Week 48 and Week 60

    Time frame: Week 48 and Week 60

  3. Participants achieving an ETDRS letter score of at least 69 (approximate 20/40 Snellen equivalent) at Week 48

    Time frame: Week 48

  4. Participants with no Intraretinal fluid (IRF) and/or no Subretinal fluid (SRF) in the center subfield at Week 48

    Time frame: Week 48

  5. Change from baseline in central subfield thickness (CST) at Week 48

    Time frame: Week 0 (Baseline) to Week 48

  6. Change from baseline in leakage on fluorescein angiography (FA) at Week 48

    Time frame: Week 0 (Baseline) to Week 48

  7. Change from baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ) total score at Week 48

    Time frame: Week 0 (Baseline) to Week 48

  8. Occurrence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Weeks 48 and 60

    Time frame: Week 48 to Week 60

  9. Participants developing a treatment-emergent Anti-drug antibody (ADA) response or Nabs to aflibercept through EOS at Week 60

    Time frame: Week 60

  10. Systemic exposure to aflibercept as assessed by plasma concentrations of free, adjusted bound, and total aflibercept from baseline through Week 48

    Time frame: Week 0 (Baseline) to Week 48

07

Study locations

52 sites
  • The Second Hospital of Anhui medical university
    Hefei, Anhui 230601, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730030, China
  • Guangdong Provincial Hospital of TCM
    Guangzhou, Guangdong 510120, China
  • Guangzhou First People Hospital
    Guangzhou, Guangdong 510180, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong 510280, China
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • Luoyang Third People's Hospital
    Luoyang, Henan 471002, China
  • Renmin Hosp., Wuhan Univ.
    Wuhan, Hubei 430040, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210006, China
  • Affiliated hospital of Nantong university
    Nantong, Jiangsu 226006, China
  • The First Affiliated Hospital of NanChang University
    Nanchang, Jiangxi 330006, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330200, China
  • The Second Hospital of Jilin University
    Changchun, Jilin 130000, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130061, China
  • Aier Eye Hospital (LIAONING)
    Shenyang, Liaoning, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030032, China
  • Sichuan University West China Hospital
    Chengdu, Sichuan MISSING, China
  • Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang 317099, China
  • Zhengzhou Second People's Hospital
    Erqi, Zhengzhou 450015, China
  • Beijing Aier Intech Eye Hospital
    Beijing, 100000, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, 100050, China
  • Capital Medical University (CMU) - Beijing Tongren Hospital
    Beijing, 100062, China
  • Central South University - The Second Xiangya Hospital
    Changsha, 410007, China
  • Chengdu Aier Ophthalmology Hospital
    Chengdu, 610041, China
  • Chengdu University of Traditional Chinese Medicine - Teaching Hospital (Sichuan Province Traditional Chinese Medicine Hospital)
    Chengdu, 610072, China
  • The First Affiliated Hospital of Chongqing Medical Universit
    Chongqing, 400042, China
  • Guangzhou Aier Ophthalmology Hospital
    Guangzhou, 510288, China
  • Zhejiang University School of Medicine - The Second Affiliated Hospital
    Hangzhou, 310003, China
  • Hebei eye hospital
    Hebei, 050010, China
  • Henan Provincial Eye Hospital
    Henan, 450008, China
  • Jinan Second People's Hospital
    Jinan, 250021, China
  • Eye hospital of Shandong First Medical University
    Jinan, 250299, China
  • People's Hospital of Ningxia Hui Autonomous Region - Opthalmology
    Ningxia, 750002, China
  • Shandong University of Traditional Chinese Medicine Affiliated Ophthalmology Hospital
    Shandong, 250299, China
  • Weifang Ophthalmology Hospital
    Shandong, 261041, China
  • Shanghai eye disease prevention and control center
    Shanghai, 200041, China
  • Shanghai General Hospital
    Shanghai, 200080, China
  • Shanghai Jiao Tong University School of Medicine (SJTUSM) - XinHua Hospital
    Shanghai, 200092, China
  • Eye & Ent Hospital of Fudan University
    Shanghai, 200126, China
  • Joint Shantou International Eye Center (JSIEC)Shantou University & the Chinese University of Hong Kong
    Shantou, 515041, China
  • Shanxi Eye Hospital
    Shanxi, 030002, China
  • Shenyang He Eye Specialist Hospital
    Shenyang, 110034, China
  • The Fourth People's Hospital of Shenyang
    Shenyang, 110082, China
  • Shijiazhuang People's Hospital
    Shijiazhuang, 050011, China
  • Tianjin Medical University Eye Hospital
    Tianjin, 300384, China
  • Eye Hospital of Wenzhou Medical University
    Wenzhou, 325027, China
  • Xi'an People's Hospital (Xi'an Fourth Hospital)
    Xi'an, 710005, China
  • Xianyang First People's Hospital
    Xianyang, 712099, China
  • Grantham Hospital
    Hong Kong, Hong Kong SAR 00000, Hong Kong
  • Tseung Kwan O Hospital
    Tseung Kwan O, New Territories 00000, Hong Kong
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Dec 2025, 19 months.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 19 months is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 21, 2024
StartActual
May 29, 2024
Primary completionActual
Dec 29, 2025
CompletionActual
Mar 25, 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06422507
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 21, 2024
Start date
May 29, 2024
Primary completion
Dec 29, 2025
Completion
Mar 25, 2026
Last update
Mar 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion